BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neong SF, Adebayo D, Wong F. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. Expert Rev Gastroenterol Hepatol 2019;13:293-305. [PMID: 30791777 DOI: 10.1080/17474124.2018.1555469] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Premkumar M, Anand AC. Overview of Complications in Cirrhosis. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.04.021] [Reference Citation Analysis]
2 Siqueira MR, Pace FHL, Limongi TM, Henrique DMN, Mira PAC, Oliveira TMD, Oliveira CC, Aguiar AS, Malaguti C. Factors associated with the perceived benefits and barriers to physical activity in liver cirrhosis. Rev Assoc Med Bras (1992) 2021;67:271-6. [PMID: 34406252 DOI: 10.1590/1806-9282.67.02.20200692] [Reference Citation Analysis]
3 Ali B, Salim A, Alam A, Zuberi BF, Ali Z, Azam Z, Kamani L, Farooqi JI, Salih M, Nawaz AA, Chaudhry AA, Hashmi ZY, Siddique M. HEP-Net opinion on the management of ascites and its complications in the setting of decompensated cirrhosis in the resource constrained environment of Pakistan. Pak J Med Sci 2020;36:1117-32. [PMID: 32704299 DOI: 10.12669/pjms.36.5.2407] [Reference Citation Analysis]
4 Li Y, Dong J, Zhou Y, Ye X, Cai Z, Zhang X, Shen L, Zhang M, Zhang W, Cai J. Therapeutic effects of CXCL9-overexpressing human umbilical cord mesenchymal stem cells on liver fibrosis in rats. Biochem Biophys Res Commun 2021;584:87-94. [PMID: 34775285 DOI: 10.1016/j.bbrc.2021.10.078] [Reference Citation Analysis]
5 Guo C, Liu Q, Wang Y, Li J. Umbilical Hernia Repair in Cirrhotic Patients With Ascites: A Systemic Review of Literature. Surg Laparosc Endosc Percutan Tech 2020;31:356-62. [PMID: 33347087 DOI: 10.1097/SLE.0000000000000891] [Reference Citation Analysis]
6 Gu D, Tong C, Zhao XA, Xiang XX. Progress in research of factors associated with esophageal and gastric variceal rebleeding in cirrhosis. Shijie Huaren Xiaohua Zazhi 2022; 30(5): 230-234 [DOI: 10.11569/wcjd.v30.i5.230] [Reference Citation Analysis]
7 Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells 2020;9:E875. [PMID: 32260126 DOI: 10.3390/cells9040875] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 24.5] [Reference Citation Analysis]
8 Perry WP, Barrett JJ, Secic M, Ehieli WL, Leder RA, Marin D, Nelson RC, Gupta RT. Can procedure time for paracentesis be optimized based on bottle selection? Abdom Radiol (NY) 2021;46:4062-7. [PMID: 33783568 DOI: 10.1007/s00261-021-03033-8] [Reference Citation Analysis]
9 Santo MCCDE, Gryschek RCB, Farias AQ, Andraus W, Carvalho NB, Leite OHM, Castro FC, Cerri GG, Hypólitti GH, Carnevale FC, Assis AM. Management and treatment of decompensated hepatic fibrosis and severe refractory Schistosoma mansoni ascites with transjugular intrahepatic portosystemic shunt. Rev Inst Med Trop Sao Paulo 2022;64:e26. [PMID: 35384957 DOI: 10.1590/S1678-9946202264026] [Reference Citation Analysis]
10 De Matthaeis N, Di Stasi C, Pizzolante F, Manfredi R, Rapaccini GL, Miele L. Multimodal sequential treatment for occluded TIPS: Case report and review of literature. Clin Mol Hepatol 2020;26:227-30. [PMID: 31735021 DOI: 10.3350/cmh.2019.0056] [Reference Citation Analysis]
11 Li M, Bi Z, Huang Z. Impact of Vaptans on Clinical Outcomes in Cirrhosis Patients: A Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2019;10:1365. [PMID: 31824315 DOI: 10.3389/fphar.2019.01365] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]